Metformin Alters the Duodenal Microbiome and Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity.

J. Jacobs,Meg Hauer,Tien S. Dong,G. Eibl,Hui-Hua Chang,E. Rozengurt,William Katzka,V. Lagishetty

DOI: https://doi.org/10.1152/ajpgi.00170.2019

2019-12-01

Abstract:BACKGROUND Pancreatic ductal adenocarcinoma's (PDAC) growing incidence has been linked to the rise in obesity and type 2 diabetes mellitus. In previous work we have shown that metformin can prevent the increased incidence of PDAC in a KrasG12D mouse model subjected to a diet high in fat and calories (HFCD). One potential way that metformin can affect the host is through alterations in the gut microbiome. Therefore, we investigated microbial associations with PDAC development and metformin use in the same mouse model. METHODS LSL-KrasG12D/+; p48-Cre (KC) mice were given control diet (CD), HFCD, or HFCD with 5 mg/ml metformin in drinking water for 3 months. 16S rRNA sequencing was performed at the end of the 3 months to characterize microbiome composition of duodenal mucosal, duodenal luminal, and cecal luminal samples. RESULTS KC mice on a HFCD demonstrated depletion of intact acini and formation of advanced pancreatic intraepithelial neoplasia. This effect was completely abrogated by metformin treatment. HFCD was associated with significant changes in microbial composition and diversity in the duodenal mucosa and lumen, much of which was prevented by metformin. In particular, Clostridium sensu stricto negatively correlated with percent intact acini and seemed to be inhibited by the addition of metformin while on a HFCD. CONCLUSION Administration of metformin eliminated PDAC formation in KC mice. This change was associated with significant microbial changes in both the mucosal and luminal microbiome of the duodenum. This suggests that the microbiome may be a potential mediator of the chemo-preventive effects of metformin.

Medicine,Biology,Environmental Science